StocksMedium•5 November 2026•
1 min read
Janux Therapeutics Beats Q3 Revenue and Earnings Estimates
Key Facts
1Janux Therapeutics reported a GAAP EPS of -$0.34, beating analyst estimates by $0.14.
2The company's revenue reached $9.29M, surpassing estimates by $2.87M.
Janux Therapeutics reported a GAAP EPS loss of $0.34 for the third quarter, beating analyst estimates by $0.14. Seeking Alpha reported that the company's revenue reached $9.29 million, which surpassed expectations by $2.87 million.
JANX closed at $18.18 on November 4, 2026, with the stock trading between a low of $17.43 and a high of $18.33 during that session. The company maintains a cash position and short-term investments totaling $945.7 million to support its clinical-stage programs, despite remaining a loss-making entity.